Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Inc. (RLMD) — Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance. Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.Added to the Russell 2000® and Russell 3000® Indexes effective June 2

Source: GlobeNewswire — read the full announcement there.

See our Relmada Therapeutics company profile for background, links, and more Relmada Therapeutics news.